Erdafitinib

立即咨询

Erdafitinib

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1346242-81-6

包装与价格：

包装	价格(元)
5mg	询价
10mg	询价

化学性质

Storage	Store at -20°C
M.Wt	446.54
Cas No.	1346242-81-6
Formula	C₂₅H₃₀N₆O₂
Synonyms	JNJ-42756493
Solubility	insoluble in H2O; ≥15 mg/mL in EtOH; ≥54.5 mg/mL in DMSO
Chemical Name	N1-(3,5-dimethoxyphenyl)-N2-isopropyl-N1-(3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl)ethane-1,2-diamine
Canonical SMILES	CN(N=C1)C=C1C2=NC3=CC(N(CCNC(C)C)C4=CC(OC)=CC(OC)=C4)=CC=C3N=C2
运输条件	蓝冰运输或根据您的需求运输。
一般建议	为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

Erdafitinib is an effective, selective and oral bioactive pan-fibroblast growth factor receptor FGFR inhibitor with potential anti-tumor activity and inhibits FGFR1/2/3/4 with IC50s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.In vitro, Erdafitinib-treated cells reduced proliferation, increased apoptotic death, and reduced cell survival. In vivo experiments, Erdafitinib treatment delayed the growth of NCI-H716 tumors, and when drug treatment was withdrawn, tumor volume increased

试验操作

Cell experiment:[1]
Cell lines	Various colorectal cancer (CRC) cell lines with FGFR wild type (Caco2 and HCA7) and FGFR2 amplification (HCT116, NCI-H716)
Reaction Conditions	72 h incubation
Applications	Erdafitinib significantly decreased cell growth and survival of NCI-H716 cells at concentrations of ≧ 0.5nM, whereas ≧ 5000 nM was required for all other cell lines, including Caco2.
Animal experiment:[1]
Animal models	NMRI nu/nu female mice xenografted with NCI-H716 cellse
Dosage form	40 mg/kg Administered in the morning three times a week for three weeks by gavage
Applications	In vivo, growth of NCI-H716 tumors was delayed by 5 days by drug treatment alone, although when drug delivery was stopped the relative tumor volume increased compared to control.
Note	The technical data provided above is for reference only.
	References: 1. Verstraete M, Debucquoy A, Gonnissen A, et al. In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer. BMC Cancer, 2015, 15: 946.